See more : International Flavors & Fragrances Inc. (IFF) Income Statement Analysis – Financial Results
Complete financial analysis of Anika Therapeutics, Inc. (ANIK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anika Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- VK Company Limited (VKCO.IL) Income Statement Analysis – Financial Results
- PlayAGS, Inc. (AGS) Income Statement Analysis – Financial Results
- Jaiprakash Associates Limited (JPASSOCIAT.NS) Income Statement Analysis – Financial Results
- Sanyei Corporation (8119.T) Income Statement Analysis – Financial Results
- Gufic Biosciences Limited (GUFICBIO.NS) Income Statement Analysis – Financial Results
Anika Therapeutics, Inc. (ANIK)
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 166.66M | 156.24M | 147.79M | 130.46M | 114.61M | 105.56M | 113.42M | 103.38M | 93.00M | 105.59M | 75.08M | 71.36M | 64.78M | 55.56M | 40.14M | 35.78M | 30.83M | 26.84M | 29.84M | 26.47M | 15.40M | 13.19M | 11.31M | 16.34M | 13.50M | 13.90M | 12.00M | 1.20M | 3.40M | 4.70M | 2.20M |
| Cost of Revenue | 63.57M | 62.66M | 64.85M | 61.43M | 28.75M | 31.28M | 27.36M | 24.03M | 21.05M | 20.93M | 22.77M | 28.99M | 26.78M | 23.83M | 13.67M | 13.19M | 11.88M | 11.12M | 11.14M | 9.95M | 8.01M | 8.11M | 8.23M | 8.67M | 5.30M | 5.20M | 4.40M | 700.00K | 2.80M | 3.70M | 1.90M |
| Gross Profit | 103.09M | 93.58M | 82.94M | 69.03M | 85.86M | 74.28M | 86.06M | 79.35M | 71.95M | 84.66M | 52.32M | 42.37M | 37.99M | 31.73M | 26.47M | 22.59M | 18.95M | 15.72M | 18.69M | 16.52M | 7.40M | 5.08M | 3.08M | 7.66M | 8.20M | 8.70M | 7.60M | 500.00K | 600.00K | 1.00M | 300.00K |
| Gross Profit Ratio | 61.85% | 59.89% | 56.12% | 52.91% | 74.92% | 70.37% | 75.87% | 76.76% | 77.36% | 80.18% | 69.68% | 59.38% | 58.65% | 57.11% | 65.94% | 63.14% | 61.46% | 58.58% | 62.65% | 62.41% | 48.03% | 38.51% | 27.26% | 46.91% | 60.74% | 62.59% | 63.33% | 41.67% | 17.65% | 21.28% | 13.64% |
| Research & Development | 32.69M | 28.18M | 27.33M | 23.43M | 16.67M | 18.19M | 18.79M | 10.73M | 8.99M | 8.14M | 7.06M | 5.39M | 6.17M | 6.87M | 8.18M | 7.40M | 4.36M | 3.62M | 4.73M | 4.09M | 2.60M | 3.93M | 4.28M | 3.26M | 4.20M | 2.00M | 2.00M | 0.00 | 1.30M | 1.50M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 0.00 | 900.00K | 700.00K | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 95.85M | 84.79M | 74.10M | 60.06M | 34.95M | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 2.60M | 900.00K | 700.00K | 1.90M |
| Other Expenses | 62.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54B | 0.00 | 0.00 | 2.15B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| Operating Expenses | 191.48M | 112.98M | 101.42M | 83.49M | 51.62M | 52.53M | 40.33M | 28.75M | 23.81M | 23.22M | 20.00M | 20.12M | 24.03M | 24.19M | 18.73M | 18.36M | 12.36M | 10.30M | 10.14M | 10.13M | 6.80M | 8.35M | 10.49M | 8.65M | 8.30M | 5.50M | 4.40M | 3.20M | 2.50M | 2.40M | 2.20M |
| Cost & Expenses | 254.30M | 175.64M | 166.27M | 144.93M | 80.36M | 83.81M | 67.69M | 52.77M | 44.87M | 44.15M | 42.76M | 49.11M | 50.81M | 48.02M | 32.40M | 31.55M | 24.24M | 21.41M | 21.28M | 20.08M | 14.81M | 16.46M | 18.72M | 17.32M | 13.60M | 10.70M | 8.80M | 3.90M | 5.30M | 6.10M | 4.10M |
| Interest Income | 0.00 | 654.00K | 188.00K | 498.00K | 1.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 654.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.19K | 5.26M | 182.39K | 194.62K | 4.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 14.22M | 16.35M | 15.99M | 15.00M | 7.17M | 5.91M | 4.29M | 3.73M | 3.78M | 4.71M | 4.77M | 4.53M | 4.00M | 3.32M | 1.29M | 1.43M | 818.73K | 384.06K | 459.00K | 710.00K | 1.01M | 1.10M | 1.23M | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| EBITDA | -11.23M | -4.91M | 2.62M | -12.83M | 34.25M | 27.66M | 50.02M | 54.34M | 51.91M | 61.45M | 32.03M | 26.78M | 17.97M | 10.86M | 11.18M | 5.66M | 7.41M | 5.81M | 9.01M | 14.53M | 1.60M | -2.18M | -6.18M | 214.38K | 1.10M | 3.37M | 3.50M | -2.10M | -1.60M | -1.20M | -1.60M |
| EBITDA Ratio | -6.74% | -12.42% | -26.78% | -0.47% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 42.66% | 34.74% | 27.74% | 19.54% | 27.87% | 15.82% | 24.02% | 21.65% | 30.20% | 26.82% | 10.39% | -16.53% | -54.61% | 1.31% | 5.93% | 19.42% | 26.67% | -183.33% | -47.06% | -27.66% | -72.73% |
| Operating Income | -87.64M | -19.40M | -18.48M | -14.47M | 34.25M | 21.75M | 45.73M | 50.61M | 48.13M | 61.45M | 32.61M | 19.72M | 13.97M | 7.54M | 5.59M | 4.23M | 6.59M | 5.43M | 8.55M | 6.39M | 595.00K | -3.27M | -7.41M | -983.37K | -100.00K | 3.20M | 3.20M | -2.70M | -1.90M | -1.40M | -1.90M |
| Operating Income Ratio | -52.58% | -12.42% | -12.50% | -11.09% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 43.43% | 27.63% | 21.56% | 13.57% | 13.92% | 11.81% | 21.37% | 20.22% | 28.66% | 24.14% | 3.86% | -24.83% | -65.51% | -6.02% | -0.74% | 23.02% | 26.67% | -225.00% | -55.88% | -29.79% | -86.36% |
| Total Other Income/Expenses | 2.31M | 654.00K | -188.00K | -302.00K | 1.87M | 1.46M | 473.00K | 263.00K | 120.00K | 58.14K | -127.00K | -187.78K | -182.39K | -194.62K | -2.23M | 498.51K | 2.10M | 2.10M | 1.24M | 388.71K | 144.00K | 239.00K | 662.19K | 1.17M | 1.38M | 700.00K | 200.00K | 100.00K | 0.00 | 100.00K | 0.00 |
| Income Before Tax | -85.33M | -18.75M | 2.43M | -28.62M | 36.12M | 23.21M | 46.20M | 50.87M | 48.25M | 61.51M | 32.48M | 19.53M | 13.79M | 7.34M | 5.51M | 4.73M | 8.69M | 7.53M | 9.79M | 6.78M | 739.00K | -3.03M | -6.75M | 189.49K | -100.00K | 4.40M | 3.40M | -2.60M | 0.00 | -1.30M | -1.90M |
| Income Before Tax Ratio | -51.20% | -12.00% | 1.64% | -21.94% | 31.52% | 21.99% | 40.74% | 49.21% | 51.89% | 58.25% | 43.26% | 27.37% | 21.28% | 13.22% | 13.73% | 13.21% | 28.18% | 28.05% | 32.82% | 25.61% | 4.80% | -23.02% | -59.66% | 1.16% | -0.74% | 31.65% | 28.33% | -216.67% | 0.00% | -27.66% | -86.36% |
| Income Tax Expense | -2.66M | -3.89M | -1.71M | -4.64M | 8.93M | 4.49M | 14.39M | 18.32M | 17.50M | 23.19M | 11.91M | 7.77M | 5.32M | 3.03M | 1.82M | 1.10M | 2.65M | 2.92M | 3.90M | -4.41M | -88.00K | 5.00K | 9.08K | 15.94K | 2.20M | 100.00K | 100.00K | -100.00K | 100.00K | -100.00K | -300.00K |
| Net Income | -82.67M | -14.86M | 4.13M | -23.98M | 27.19M | 18.72M | 31.82M | 32.55M | 30.76M | 38.32M | 20.57M | 11.76M | 8.47M | 4.32M | 3.69M | 3.63M | 6.04M | 4.60M | 5.89M | 11.19M | 827.00K | -3.04M | -6.76M | 173.55K | -2.50M | 4.30M | 3.30M | -2.70M | -2.00M | -1.40M | -1.60M |
| Net Income Ratio | -49.60% | -9.51% | 2.80% | -18.38% | 23.73% | 17.74% | 28.05% | 31.48% | 33.07% | 36.29% | 27.40% | 16.48% | 13.07% | 7.77% | 9.19% | 10.14% | 19.58% | 17.15% | 19.75% | 42.28% | 5.37% | -23.05% | -59.74% | 1.06% | -18.52% | 30.94% | 27.50% | -225.00% | -58.82% | -29.79% | -72.73% |
| EPS | -5.64 | -1.02 | 0.29 | -1.69 | 1.93 | 1.30 | 2.18 | 2.22 | 2.06 | 2.61 | 1.46 | 0.89 | 0.65 | 0.34 | 0.32 | 0.32 | 0.55 | 0.43 | 0.57 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.26 | 0.38 | 0.60 | -0.56 | -0.61 | -0.45 | -0.51 |
| EPS Diluted | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 | 1.27 | 2.11 | 2.15 | 2.01 | 2.51 | 1.39 | 0.82 | 0.62 | 0.32 | 0.32 | 0.32 | 0.53 | 0.41 | 0.52 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.24 | 0.34 | 0.44 | -0.56 | -0.61 | -0.45 | -0.51 |
| Weighted Avg Shares Out | 14.66M | 14.56M | 14.40M | 14.22M | 14.12M | 14.44M | 14.58M | 14.68M | 14.93M | 14.68M | 14.09M | 13.26M | 13.06M | 12.62M | 11.39M | 11.31M | 11.06M | 10.64M | 10.41M | 11.42M | 9.95M | 9.93M | 9.93M | 9.87M | 9.74M | 9.89M | 5.00M | 4.82M | 3.28M | 3.11M | 3.14M |
| Weighted Avg Shares Out (Dil) | 14.66M | 14.56M | 14.63M | 14.22M | 14.37M | 14.69M | 15.07M | 15.12M | 15.32M | 15.27M | 14.83M | 14.34M | 13.75M | 13.65M | 11.56M | 11.46M | 11.45M | 11.16M | 11.43M | 11.42M | 10.85M | 9.93M | 9.93M | 10.04M | 10.22M | 11.01M | 7.50M | 4.82M | 3.28M | 3.11M | 3.14M |
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2024 Earnings Conference Call May 8, 2024 5:30 PM ET Company Participants Mark Namaroff - Vice President of Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz...
Anika Announces CFO Transition
Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024
Anika Reports First Quarter 2024 Financial Results
Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800...
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of...
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8,...
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on March 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500...
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the...
Source: https://incomestatements.info
Category: Stock Reports